Bristol Hopes REMS Proposal Can Overcome Safety Concerns About Belatacept
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.